Your News article on Newcastle disease virus (NDV) as a cancer treatment (1) pays long-needed attention to this promising field. But it also presents a one-sided and distorted picture of the history of this development.
Intense interest in NDV as a cancer treatment originated in the 1960s. This interest then branched in two directions. After using live NDV in a single patient (2) , Dr. Cassel developed tumor oncolysates, which contain killed viruses. He has worked with them ever since.
The other approach was to use the live NDV itself. This approach was pioneered by one of us (L. Csatary) who has worked with the virus intensively for more than 30 years. Although your article calls Csatary "elusive," the scientific record (including 14 MEDLINE® citations) shows otherwise. Csatary's work did not originate in the 1990s, as the reader might suppose. (The first article by him that you cite (3) dates from 1993.) In fact, his first publication was in Lancet in 1971 and summarized earlier work (4) . This fact is even embedded in the name of his viral strain, MTH-68, which stands for "More Than Hope 1968" and refers to the year in which he developed the strain with which he continues to work.
You also fail to mention some of his most significant recent publications: a best-case series published in Anticancer Research in January-February, 1999 (5) and the breakthrough case of a complete remission of high-grade glioblastoma by the use of MTH-68, which is described in a recent issue of Journal of the American Medical Association (6) . We find this omission curious, since your reporter contacted the Csatarys about this case.
Your article also repeats unfounded allegations about the Hungarian clinical trial of MTH-68, implying that it was a shady commercial operation. The claim that 4000 people were treated in Hungary with MTH-68 is completely untrue. This figure represents those who, at their own request, were placed on a waiting list but who never received treatment.
Raising the specter of "criminal sanctions" is also highly damaging to the Csatarys and MTH-68. The Csatarys' involvement was to provide the treatment protocol, to advise, and to cover all expenses. Aside from humanitarian concerns, the purpose of the clinic was to expedite the accumulation of data, with the goal of arranging randomized clinical trials at independent institutions. Furthermore, to allude to two unspecified websites that "[champion] the benefits of MTH-68" also conveys the erroneous impression that this product is being commercialized via the Internet. Neither the Csatarys themselves nor the United Cancer Research Institute maintain a website, nor do they have any affiliation with the minuscule number of websites that even mention this treatment.
In sum, your article fails to mention L. Csatary's most relevant publications, denies him credit and priority in the field of live NDV therapy, carelessly allows his name to be linked to allegations of criminality, and is harmful to his reputation and life's work. This certainly merits, at the least, an apology. Csatary's other publications were anecdotal reports. A letter (3) reported seeing tumor regressions after treating three patients with live virus. A 1999 article (4) described the effects of treating four patients. Another letter (5) reported tumor shrinkage and neurologic improvement in a single glioblastoma patient treated with NDV.
I had noted Csatary's comment in the 1999 article (4) that "over 300 patients have been treated at a private clinic in Budapest" and was anxious to find out the results obtained with those patients. I attempted to contact Csatary at the United Cancer Research Institute (UCRI). Although he never responded, Eva Csatary advised me that they had communicated their best-case series of cancer patients treated with NDV therapy to the National Cancer Institute (NCI). As I reported in my article, NCI scientists were unable to evaluate the effectiveness of the therapy from the information provided.
An article (6) written by the Presidium of the Hungarian Scientific Medical Council stated that the Csatary Center for Virus Therapy in Budapest had requested permission in 1994 to treat 300 patients with NDV. The Council granted this permission but expressly did not approve treatment of additional patients until "certification of the success of the treatment by uninvolved specialists and [of] a vaccine that conforms to [World Health Organization] specifications" (6) . In 1998, an independent committee evaluated a report provided by the Csatary Center and concluded that "the treatment did not conform in any way to the conditions under which the permit was granted" and that "it is seriously objectionable that, according to the data provided by the Center, 4004
